Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:53 AM
Ignite Modification Date:
2025-12-25 @ 2:53 AM
NCT ID:
NCT01110733
Eligibility Criteria:
Inclusion Criteria:
* Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):
* Aggressive natural killer (NK)-cell leukemia
* Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+)
* Angioimmunoblastic T-cell lymphoma
* Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
* PTCL, not otherwise specified (NOS)
* T/NK-cell lymphoma, nasal type
* Enteropathy-type intestinal lymphoma
* Hepatosplenic T-cell lymphoma
* Subcutaneous panniculitis T-cell lymphoma
* Transformed mycosis fungoides (at diagnosis of transformation)
* T-cell prolymphocytic leukemia (T-PLL)
* Cutaneous gamma/delta (γ/δ) T-cell lymphoma
* Cutaneous aggressive CD8+ T-cell lymphoma
* Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
* Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)
* Other T-Cell lymphomas that are not listed in the Exclusion Criteria
* Patient gives written informed consent
Exclusion Criteria:
* Patient has other T- or NK-cell malignancies including:
* Precursor T/NK neoplasms
* T-cell large granular lymphocytic leukemia
* Mycosis fungoides, other than transformed mycosis fungoides
* Sézary syndrome
* Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT01110733
Study Brief:
Protocol Section:
NCT01110733